<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565315</url>
  </required_header>
  <id_info>
    <org_study_id>180113</org_study_id>
    <secondary_id>18-I-0113</secondary_id>
    <nct_id>NCT03565315</nct_id>
  </id_info>
  <brief_title>Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults</brief_title>
  <official_title>VRC 610: Phase I Safety and Pharmacokinetics Study to Evaluate a Human Monoclonal Antibody (MAB) VRC-HIVMAB095-00-AB (10E8VLS) Administered Alone or Concurrently With MAB VRC-HIVMAB075-00-AB (VRC07-523LS) Via Subcutaneous Injection in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Human immunodeficiency virus (HIV) infection is a serious disease. There is no cure or&#xD;
      vaccine to prevent infection. Using antibodies might be a good way to treat or prevent HIV.&#xD;
      Antibodies are naturally made by the body to fight germs. Researchers want to test if two&#xD;
      antibodies made artificially in a lab can help to prevent HIV infection. The antibodies are&#xD;
      10E8VLS and VRC07-523LS.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To see if 10E8VLS and VRC07-523LS are safe and well-tolerated and how long they stay in the&#xD;
      blood.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy adults ages 18-60&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Volunteers were screened in another protocol.&#xD;
&#xD;
      Participants were enrolled in 1 of 4 groups:&#xD;
&#xD;
      Group 1 participants were enrolled to receive 1 dose of 10E8VLS.&#xD;
&#xD;
      Group 2 participants were enrolled to receive 3 doses of 10E8VLS.&#xD;
&#xD;
      Group 3 participants were enrolled to receive 1 dose of both 10E8VLS and VRC07-523LS.&#xD;
&#xD;
      Group 4 participants were enrolled to receive 3 doses of both 10E8VLS and VRC07-523LS.&#xD;
&#xD;
      Participants in Groups 1 and 3 were expected to be enrolled about 13 visits over 24 weeks.&#xD;
&#xD;
      Participants in Groups 2 and 4 were expected to be enrolled about 26 visits over 48 weeks.&#xD;
&#xD;
      Participants were weighed before each dose. Women may have had a pregnancy test. Participants&#xD;
      had blood collected.&#xD;
&#xD;
      A small needle injected each dose into fatty tissue of the belly, upper arm, or thigh.&#xD;
      Participants received between 1 and 8 injections per dose depending on their weight. Heavier&#xD;
      participants received more injections.&#xD;
&#xD;
      Participants received a ruler and thermometer. They checked their temperature for 3 days&#xD;
      after injection(s) and measured any redness, swelling, or bruising at the injection site.&#xD;
&#xD;
      At non-injection visits, participants had blood drawn and were checked for health changes or&#xD;
      problems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VRC 610:&#xD;
&#xD;
      A Phase I Safety and Pharmacokinetics Study to Evaluate a Human Monoclonal Antibody (MAB)&#xD;
      VRC-HIVMAB095-00-AB (10E8VLS) Administered Alone or Concurrently with MAB VRC-HIVMAB075-00-AB&#xD;
      (VRC07-523LS) Via Subcutaneous Injection in Healthy Adults&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This first-in-human, open-label study evaluated MAb 10E8VLS (VRC-HIVMAB095-00-AB)&#xD;
      administered alone or concurrently (i.e., at the same visit) with MAb VRC07-523LS&#xD;
      (VRC-HIVMAB075-00-AB) in healthy adults ages 18 to 60. The primary hypothesis was that&#xD;
      administrations of 10E8VLS alone and concurrently with VRC07-523LS will be well-tolerated in&#xD;
      healthy adults. A secondary hypothesis was that both broadly neutralizing monoclonal&#xD;
      antibodies (bNAbs) will be detectable in human sera with a definable half-life.&#xD;
&#xD;
      Product Description:&#xD;
&#xD;
      The 10E8VLS and VRC07-523LS bNAbs target the HIV-1 envelope at distinct epitopes: 10E8VLS&#xD;
      recognizes the membrane proximal external region (MPER) and proximal viral membrane lipid of&#xD;
      gp41, while VRC07-523LS recognizes the CD4 binding site of gp120. Both antibodies are human&#xD;
      in origin, contain two amino acid modifications within the C-terminus of the heavy chain&#xD;
      constant region designed to improve antibody half-life in vivo, and were developed by the&#xD;
      VRC/NIAID/NIH. The 10E8VLS and VRC07-523LS bNAbs were manufactured under current Good&#xD;
      Manufacturing Practice (cGMP) regulations at the VRC Pilot Plant operated under contract by&#xD;
      the Vaccine Clinical Materials Program (VCMP), Leidos Biomedical Research, Inc., Frederick,&#xD;
      MD.&#xD;
&#xD;
      The 10E8VLS drug product was supplied at a concentration of 100 mg/mL in a sterile, aqueous,&#xD;
      buffered solution of 5.25 mL in single-use 10 mL glass vials. The VRC07-523LS drug product&#xD;
      was supplied at a concentration of 100 mg/mL in an isotonic, sterile solution of 6.25 mL in&#xD;
      single-use 10 mL glass vials. Each drug product was prepared for administration in separate&#xD;
      syringes.&#xD;
&#xD;
      Participants:&#xD;
&#xD;
      Healthy adults, 18-60 years of age.&#xD;
&#xD;
      Study Plan:&#xD;
&#xD;
      This open-label study included 4 dosing regimens of either 10E8VLS (5 mg/kg) administered&#xD;
      alone or 10E8VLS (5 mg/kg) and VRC07-523LS (5 mg/kg). All injections were administered by the&#xD;
      subcutaneous (SC) route. For Groups 1 and 2, 10E8VLS was to be administered once or&#xD;
      three-times at 12-week intervals. For Groups 3 and 4, 10E8VLS and VRC07-523LS were to be&#xD;
      administered once or three-times at 12-week intervals, respectively. Enrollment began with&#xD;
      Groups 1 and 2, followed by Groups 3 and 4.&#xD;
&#xD;
      VRC 610 Study Schema:&#xD;
&#xD;
        -  Group 1; Study Product: 10E8VLS; Planned Participants per Group: 3; Dose Administered&#xD;
           SC: 5 mg/kg; Day 0&#xD;
&#xD;
        -  Group 2; Study Product: 10E8VLS; Planned Participants per Group: 3; Dose Administered&#xD;
           SC: 5 mg/kg; Day 0, Week 12*, Week 24*&#xD;
&#xD;
        -  Group 3 (a,b); Study Product: 10E8VLS+VRC07-523LS; Planned Participants per Group: 5;&#xD;
           Dose Administered SC: 5 mg/kg of each MAb; Day 0&#xD;
&#xD;
        -  Group 4 (a,b); Study Product: 10E8VLS+VRC07-523LS; Planned Participants per Group: 5;&#xD;
           Dose Administered SC: 5 mg/kg of each MAb; Day 0, Week 12*, Week 24*&#xD;
&#xD;
        -  Total Planned Participants = 16&#xD;
&#xD;
        -  Total Actual Participants = 9 (c)&#xD;
&#xD;
      (*)Participants received only one product administration on Day 0 because of the voluntary&#xD;
      study pause and termination by Investigational New Drug (IND) Sponsor/Principal Investigator&#xD;
      (PI) decision.&#xD;
&#xD;
        1. Enrollment into Group 3 and 4 commenced after positive protocol safety review team&#xD;
           (PSRT) review of safety data from Groups 1 and 2&#xD;
&#xD;
        2. 10E8VLS and VRC07-523LS were provided in separate syringes and administered at the same&#xD;
           visit.&#xD;
&#xD;
        3. The expected enrollment was 16 participants; however, enrollment was voluntarily paused&#xD;
           by the IND Sponsor/PI and the study ultimately stopped after several Grade 2 and Grade 3&#xD;
           redness local reactogenicity reactions were observed at 10E8VLS injection sites.&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      Study participation was expected to be approximately 24 weeks for participants in Groups 1&#xD;
      and 3, and 48 weeks for participants in Groups 2 and 4. Participants in the repeat-dose&#xD;
      groups (2 and 4) were converted to a modified schedule per protocol. Study participation for&#xD;
      all participants was approximately 24 weeks after Day 0 product administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor/PI voluntarily paused and stopped study after observing several Grade 2 and Grade 3&#xD;
    redness local reactogenicity reactions at 10E8VLS injection sites&#xD;
  </why_stopped>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Actual">March 4, 2019</completion_date>
  <primary_completion_date type="Actual">March 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of Product Administration</measure>
    <time_frame>3 days after product administration</time_frame>
    <description>Local symptoms were recorded by participants using a 3-day diary. Solicited local symptoms include pain/tenderness, bruising, redness, swelling, and pruritus (itchiness) at the product administration site. Clinicians reviewed the diary with the participant and collected resolution information for any symptoms that were not resolved within 3 days. Participants were counted once for each symptom at the worst severity if they experienced the symptom at any severity during the reporting period. The number reported for &quot;Any Local Symptom&quot; is the number of participants reporting any local symptom at the worst severity. Reactogenicity grading was done by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Product Administration</measure>
    <time_frame>3 days after product administration</time_frame>
    <description>Participants recorded 3-day systemic symptoms in a diary after each study product administration. Solicited systemic symptoms include: unusually tired/feeling unwell, muscles aches, headache, chills, nausea, temperature and joint pain. Participants recorded highest measured temperature daily. Clinicians reviewed the diary with the participant and collected resolution information for any symptoms that were not resolved within 3 days. Participants were counted once for each symptom at the worst severity if they indicated experiencing the symptom at any severity during the reporting period. The number reported for &quot;Any Systemic Symptom&quot; is the number of participants reporting any systemic symptom at the worst severity. Reactogenicity grading was done by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Unsolicited Non-Serious Adverse Events</measure>
    <time_frame>Up to 24 weeks after product administration</time_frame>
    <description>Unsolicited adverse events (AEs) collected during the period from study product administration at Day 0 through 56 days after product administration. After the indicated time period through the last expected study visit at 24 weeks after product administration, only new chronic medical conditions collected as unsolicited AEs. The number reported is the number of participants who experienced at least one AE in the reporting period. A participant with multiple experiences of the same event is counted once using the event of worst severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Up to 24 weeks after product administration</time_frame>
    <description>Serious adverse events (SAEs) collected during the period from study product administration at Day 0 through 24 weeks after the product administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</measure>
    <time_frame>Up to 24 weeks after product administration</time_frame>
    <description>Cmax is the peak serum concentration that 10E8VLS achieves after it has been administered: it is determined as maximum value on the summary pharmacokinetic (PK) curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1-4, 8, 12, 16, 20 and 24 post-injection; Groups 2 and 4: Pre-injection (baseline), and 24, 48 and 72 hours post injection, and Weeks 1, 2, 4, 8, 12-14, 16, 20 and 24 post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</measure>
    <time_frame>Up to 24 weeks after product administration</time_frame>
    <description>Tmax is the time it takes to reach Cmax of 10E8VLS after it has been administered; it is determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1-4, 8, 12, 16, 20 and 24 post-injection; Groups 2 and 4: Pre-injection (baseline), and 24, 48 and 72 hours post injection, and Weeks 1, 2, 4, 8, 12-14, 16, 20 and 24 post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC0-28D) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</measure>
    <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
    <description>The AUC0-28D represents the total drug exposure in 28 days after 10E8VLS administration; it is determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4 Week Mean Serum Concentration of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</measure>
    <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
    <description>The mean of individual participant 10E8VLS serum concentrations. The overall population was analyzed as all participants received only one 10E8VLS administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance Rate of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</measure>
    <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
    <description>Rate of 10E8VLS elimination divided by the plasma 10E8VLS concentration; determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Half-Life (T1/2) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</measure>
    <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
    <description>Half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy Adult Immune Response</condition>
  <arm_group>
    <arm_group_label>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVMAB095-00-AB (10E8VLS)</intervention_name>
    <description>10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
    <arm_group_label>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</arm_group_label>
    <arm_group_label>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</arm_group_label>
    <arm_group_label>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group</arm_group_label>
    <arm_group_label>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVMAB075-00-AB (VRC07-523LS)</intervention_name>
    <description>VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
    <arm_group_label>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group</arm_group_label>
    <arm_group_label>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Willing and able to complete the informed consent process.&#xD;
&#xD;
               2. 18 to 60 years of age.&#xD;
&#xD;
               3. Based on history and examination, in good general health and without history of&#xD;
                  any of the conditions listed in the exclusion criteria.&#xD;
&#xD;
               4. Willing to have blood samples collected, stored indefinitely, and used for&#xD;
                  research purposes.&#xD;
&#xD;
               5. Able to provide proof of identity to the satisfaction of the study clinician&#xD;
                  completing the enrollment process.&#xD;
&#xD;
               6. Screening laboratory criteria within 84 days prior to enrollment must meet the&#xD;
                  following criteria:&#xD;
&#xD;
          -  White blood cell count (WBC): 2,500-12,000/mm^3.&#xD;
&#xD;
          -  WBC differential: Within institutional normal range or accompanied by the Principal&#xD;
             Investigator (PI) or designee approval.&#xD;
&#xD;
          -  Platelets: 125,000 - 400,000/mm^3.&#xD;
&#xD;
          -  Hemoglobin: Within institutional normal range or accompanied by PI or designee&#xD;
             approval.&#xD;
&#xD;
          -  Creatinine: less than or equal to 1.1 x Upper Limit of Normal (ULN).&#xD;
&#xD;
          -  Aspartate aminotransferase (AST): less than or equal to 1.25 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT): less than or equal to 1.25 x ULN.&#xD;
&#xD;
          -  Negative for HIV infection by an FDA approved method of detection.&#xD;
&#xD;
          -  Negative for Hepatitis B core antibody (HBcAb) and Hepatitis C virus antibody (HCV&#xD;
             Ab).&#xD;
&#xD;
        Female-Specific Criteria:&#xD;
&#xD;
        7. If a woman is of reproductive potential and sexually active with a male partner, then&#xD;
        she agrees to use an effective means of birth control from the time of study enrollment&#xD;
        until the last study visit, or to be monogamous with a partner who has had a vasectomy.&#xD;
&#xD;
        8. Negative Beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day&#xD;
        of enrollment for women presumed to be of reproductive potential.&#xD;
&#xD;
          -  EXCLUSION CRITERIA:&#xD;
&#xD;
               1. Woman who is breast-feeding, or planning to become pregnant during the study.&#xD;
&#xD;
               2. Prior receipt of licensed or investigational monoclonal antibody.&#xD;
&#xD;
               3. Weight &gt; 115 kg.&#xD;
&#xD;
               4. Any history of a severe allergic reaction with generalized urticaria, angioedema&#xD;
                  or anaphylaxis within the 2 years prior to enrollment that has a reasonable risk&#xD;
                  of recurrence during the study.&#xD;
&#xD;
               5. Hypertension that is not well controlled.&#xD;
&#xD;
               6. Receipt of any investigational study agent within 28 days prior to enrollment.&#xD;
&#xD;
               7. Any other chronic or clinically significant condition that in the opinion of&#xD;
                  investigator would jeopardize the safety or rights of the volunteer including&#xD;
                  (but not limited to): diabetes mellitus type I/II, chronic hepatitis; OR&#xD;
                  clinically significant forms of drug or alcohol abuse, asthma, autoimmune&#xD;
                  disease, psychiatric disorders, heart disease, or cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin R Gaudinski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2018-I-0113.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012 Nov 15;491(7424):406-12. doi: 10.1038/nature11544. Epub 2012 Sep 18.</citation>
    <PMID>23151583</PMID>
  </reference>
  <reference>
    <citation>Kwon YD, Georgiev IS, Ofek G, Zhang B, Asokan M, Bailer RT, Bao A, Caruso W, Chen X, Choe M, Druz A, Ko SY, Louder MK, McKee K, O'Dell S, Pegu A, Rudicell RS, Shi W, Wang K, Yang Y, Alger M, Bender MF, Carlton K, Cooper JW, Blinn J, Eudailey J, Lloyd K, Parks R, Alam SM, Haynes BF, Padte NN, Yu J, Ho DD, Huang J, Connors M, Schwartz RM, Mascola JR, Kwong PD. Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. J Virol. 2016 Jun 10;90(13):5899-5914. doi: 10.1128/JVI.03246-15. Print 2016 Jul 1.</citation>
    <PMID>27053554</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <results_first_submitted>October 22, 2020</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2020</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Prevention</keyword>
  <keyword>Broadly Neutralizing Monoclonal Antibodies</keyword>
  <keyword>First in Human Study</keyword>
  <keyword>Anti-Drug Antibody Response to 10E8VLS or VRC07-523LS</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03565315/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</title>
          <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</title>
          <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Single Dose Group</title>
          <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Multiple Dose Group* (*Only One Dose Received)</title>
          <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Product Administration Completed</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Product Administrations</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2">One Group 4 participant enrolled but did not receive product due to IND/PI voluntary study pause.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>IND Sponsor/PI Voluntary Study Pause</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population includes all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</title>
          <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</title>
          <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Single Dose Group</title>
          <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Multiple Dose Group* (*Only One Dose Received)</title>
          <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="16.1"/>
                    <measurement group_id="B2" value="27.7" spread="5.0"/>
                    <measurement group_id="B3" value="40.0" spread="0.0"/>
                    <measurement group_id="B4" value="45.0" spread="15.6"/>
                    <measurement group_id="B5" value="33.6" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21-30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51-60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.7" spread="15.1"/>
                    <measurement group_id="B2" value="80.1" spread="18.4"/>
                    <measurement group_id="B3" value="91.1" spread="0.0"/>
                    <measurement group_id="B4" value="75.7" spread="1.3"/>
                    <measurement group_id="B5" value="80.9" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of Product Administration</title>
        <description>Local symptoms were recorded by participants using a 3-day diary. Solicited local symptoms include pain/tenderness, bruising, redness, swelling, and pruritus (itchiness) at the product administration site. Clinicians reviewed the diary with the participant and collected resolution information for any symptoms that were not resolved within 3 days. Participants were counted once for each symptom at the worst severity if they experienced the symptom at any severity during the reporting period. The number reported for &quot;Any Local Symptom&quot; is the number of participants reporting any local symptom at the worst severity. Reactogenicity grading was done by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.</description>
        <time_frame>3 days after product administration</time_frame>
        <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</title>
            <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O3">
            <title>Overall 10E8VLS Groups</title>
            <description>Total number of participants who received an SC injection of 10E8VLS alone - Groups 1 and 2 only received 10E8VLS</description>
          </group>
          <group group_id="O4">
            <title>Group 3: 10E8VLS Site Only in 10E8VLS+VRC07-523LS (5 mg/kg) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O5">
            <title>Group 4: 10E8VLS Site Only in 10E8VLS+VRC07-523LS (5 mg/kg) SC Multiple Dose Group* (*Only 1 Dose)</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O6">
            <title>Overall 10E8VLS Site Only in 10E8VLS+VRC07-523LS Groups</title>
            <description>Total number of participants who received an SC injection of 10E8VLS in Groups 3 and 4 who received 10E8VLS and VRC07-523LS concurrently</description>
          </group>
          <group group_id="O7">
            <title>Group 3: VRC07-523LS Site Only in 10E8VLS+VRC07-523LS (5 mg/kg) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O8">
            <title>Group 4: VRC07-523LS Site Only- 10E8VLS+VRC07-523LS (5 mg/kg) SC Multiple Dose Group* (*Only 1 Dose)</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O9">
            <title>Overall VRC07-523LS Site Only in 10E8VLS+VRC07-523LS Groups</title>
            <description>Total number of participants who received an SC injection of VRC07-523LS in Groups 3 and 4 who received 10E8VLS and VRC07-523LS concurrently</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of Product Administration</title>
          <description>Local symptoms were recorded by participants using a 3-day diary. Solicited local symptoms include pain/tenderness, bruising, redness, swelling, and pruritus (itchiness) at the product administration site. Clinicians reviewed the diary with the participant and collected resolution information for any symptoms that were not resolved within 3 days. Participants were counted once for each symptom at the worst severity if they experienced the symptom at any severity during the reporting period. The number reported for &quot;Any Local Symptom&quot; is the number of participants reporting any local symptom at the worst severity. Reactogenicity grading was done by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.</description>
          <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain/Tenderness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local Symptom Reported</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Product Administration</title>
        <description>Participants recorded 3-day systemic symptoms in a diary after each study product administration. Solicited systemic symptoms include: unusually tired/feeling unwell, muscles aches, headache, chills, nausea, temperature and joint pain. Participants recorded highest measured temperature daily. Clinicians reviewed the diary with the participant and collected resolution information for any symptoms that were not resolved within 3 days. Participants were counted once for each symptom at the worst severity if they indicated experiencing the symptom at any severity during the reporting period. The number reported for &quot;Any Systemic Symptom&quot; is the number of participants reporting any systemic symptom at the worst severity. Reactogenicity grading was done by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.</description>
        <time_frame>3 days after product administration</time_frame>
        <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</title>
            <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O3">
            <title>Overall 10E8VLS Groups</title>
            <description>Total number of participants who received an SC injection of 10E8VLS alone - Groups 1 and 2 only received 10E8VLS</description>
          </group>
          <group group_id="O4">
            <title>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O5">
            <title>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Multiple Dose Group* (*Only 1 Dose)</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O6">
            <title>Overall 10E8VLS+VRC07-523LS Groups</title>
            <description>Total number of participants who received an SC injection of 10E8VLS and an SC injection of VRC07-523LS concurrently - Groups 3 and 4 received 10E8VLS and VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Product Administration</title>
          <description>Participants recorded 3-day systemic symptoms in a diary after each study product administration. Solicited systemic symptoms include: unusually tired/feeling unwell, muscles aches, headache, chills, nausea, temperature and joint pain. Participants recorded highest measured temperature daily. Clinicians reviewed the diary with the participant and collected resolution information for any symptoms that were not resolved within 3 days. Participants were counted once for each symptom at the worst severity if they indicated experiencing the symptom at any severity during the reporting period. The number reported for &quot;Any Systemic Symptom&quot; is the number of participants reporting any systemic symptom at the worst severity. Reactogenicity grading was done by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.</description>
          <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic Symptom</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Unsolicited Non-Serious Adverse Events</title>
        <description>Unsolicited adverse events (AEs) collected during the period from study product administration at Day 0 through 56 days after product administration. After the indicated time period through the last expected study visit at 24 weeks after product administration, only new chronic medical conditions collected as unsolicited AEs. The number reported is the number of participants who experienced at least one AE in the reporting period. A participant with multiple experiences of the same event is counted once using the event of worst severity.</description>
        <time_frame>Up to 24 weeks after product administration</time_frame>
        <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</title>
            <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Multiple Dose Group* (*Only One Dose Received)</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg each) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O5">
            <title>Overall</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Unsolicited Non-Serious Adverse Events</title>
          <description>Unsolicited adverse events (AEs) collected during the period from study product administration at Day 0 through 56 days after product administration. After the indicated time period through the last expected study visit at 24 weeks after product administration, only new chronic medical conditions collected as unsolicited AEs. The number reported is the number of participants who experienced at least one AE in the reporting period. A participant with multiple experiences of the same event is counted once using the event of worst severity.</description>
          <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Related to 10E8VLS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to VRC07-523LS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unrelated to 10E8VLS or VRC07-523LS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Serious adverse events (SAEs) collected during the period from study product administration at Day 0 through 24 weeks after the product administration.</description>
        <time_frame>Up to 24 weeks after product administration</time_frame>
        <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</title>
            <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Single Dose Group</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Multiple Dose Group* (*Only One Dose Received)</title>
            <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
          </group>
          <group group_id="O5">
            <title>Overall</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Serious adverse events (SAEs) collected during the period from study product administration at Day 0 through 24 weeks after the product administration.</description>
          <population>Participants in Groups 1 and 2 (N=6) received 10E8VLS and Groups 3 and 4 (N=2) received 10E8VLS+VRC07-523LS. Participants in Groups 2 and 4 were assigned to receive 3 repeat product administrations but received only 1 due to the voluntary termination of study product administration by the IND sponsor. The 2nd and 3rd doses for the 3 Group 2 participants assigned to receive 10E8VLS, and the single Group 4 participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
        <description>Cmax is the peak serum concentration that 10E8VLS achieves after it has been administered: it is determined as maximum value on the summary pharmacokinetic (PK) curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1-4, 8, 12, 16, 20 and 24 post-injection; Groups 2 and 4: Pre-injection (baseline), and 24, 48 and 72 hours post injection, and Weeks 1, 2, 4, 8, 12-14, 16, 20 and 24 post injection</description>
        <time_frame>Up to 24 weeks after product administration</time_frame>
        <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>All 10E8VLS 5 mg/kg SC Groups (With or Without VRC07-523LS)</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
          <description>Cmax is the peak serum concentration that 10E8VLS achieves after it has been administered: it is determined as maximum value on the summary pharmacokinetic (PK) curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1-4, 8, 12, 16, 20 and 24 post-injection; Groups 2 and 4: Pre-injection (baseline), and 24, 48 and 72 hours post injection, and Weeks 1, 2, 4, 8, 12-14, 16, 20 and 24 post injection</description>
          <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>g/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
        <description>Tmax is the time it takes to reach Cmax of 10E8VLS after it has been administered; it is determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1-4, 8, 12, 16, 20 and 24 post-injection; Groups 2 and 4: Pre-injection (baseline), and 24, 48 and 72 hours post injection, and Weeks 1, 2, 4, 8, 12-14, 16, 20 and 24 post injection</description>
        <time_frame>Up to 24 weeks after product administration</time_frame>
        <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>All 10E8VLS 5 mg/kg SC Groups (With or Without VRC07-523LS)</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
          <description>Tmax is the time it takes to reach Cmax of 10E8VLS after it has been administered; it is determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1-4, 8, 12, 16, 20 and 24 post-injection; Groups 2 and 4: Pre-injection (baseline), and 24, 48 and 72 hours post injection, and Weeks 1, 2, 4, 8, 12-14, 16, 20 and 24 post injection</description>
          <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC0-28D) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
        <description>The AUC0-28D represents the total drug exposure in 28 days after 10E8VLS administration; it is determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
        <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
        <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>All 10E8VLS 5 mg/kg SC Groups (With or Without VRC07-523LS)</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC0-28D) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
          <description>The AUC0-28D represents the total drug exposure in 28 days after 10E8VLS administration; it is determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
          <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>g*d/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322" spread="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4 Week Mean Serum Concentration of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
        <description>The mean of individual participant 10E8VLS serum concentrations. The overall population was analyzed as all participants received only one 10E8VLS administration.</description>
        <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
        <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>All 10E8VLS 5 mg/kg SC Groups (With or Without VRC07-523LS)</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>4 Week Mean Serum Concentration of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
          <description>The mean of individual participant 10E8VLS serum concentrations. The overall population was analyzed as all participants received only one 10E8VLS administration.</description>
          <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>g/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance Rate of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
        <description>Rate of 10E8VLS elimination divided by the plasma 10E8VLS concentration; determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
        <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
        <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>All 10E8VLS 5 mg/kg SC Groups (With or Without VRC07-523LS)</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance Rate of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
          <description>Rate of 10E8VLS elimination divided by the plasma 10E8VLS concentration; determined based on the summary PK curve for the overall study population.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
          <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>mL/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1309" spread="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Half-Life (T1/2) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
        <description>Half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
        <time_frame>Administration (0h) up to 28 days after product administration</time_frame>
        <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>All 10E8VLS 5 mg/kg SC Groups (With or Without VRC07-523LS)</title>
            <description>Total number of participants who received 10E8VLS administered alone or concurrently with VRC07-523LS</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Half-Life (T1/2) of 10E8VLS Administered Alone or Concurrently With VRC07-523LS</title>
          <description>Half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.&#xD;
Serum was collected at the following time points: Groups 1 and 3: Pre-injection (baseline), and 24, 48 and 72 hours post injection, followed by Weeks 1, 2, 3 and 4 post injection; Groups 2 and 4: Pre-injection (baseline) and 24, 48 and 72 hours post injection and Weeks 1, 2 and 4 post injection.</description>
          <population>Participants received 10E8VLS administered alone or concurrently with VRC07-523LS (N=8), where &quot;N&quot; signifies the number analyzed. The overall population (N=8) was analyzed for this measure as all study groups received only one 10E8VLS administration. Due to voluntary termination of study product administration by the IND sponsor, 2nd and 3rd administrations for the 3 participants assigned to receive 10E8VLS, and the one participant assigned to receive 10E8VLS+VRC07-523LS were not administered.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events (AEs) included local administration site and systemic AEs reported by participants at the worst severity through 3 days after the product administration. Unsolicited AEs were reported from the date of product administration through 56 days thereafter, and new chronic medical conditions and SAEs with onset any time following the date of last product administration through 24 weeks.</time_frame>
      <desc>Solicited AEs collected through systematic assessment and unsolicited AEs collected through non-systematic assessment represent the number and percentage of participants reporting the event. A participant with multiple experiences of the same event is counted once using the event of worst severity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group</title>
          <description>10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)</title>
          <description>10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Single Dose Group</title>
          <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: 10E8VLS+VRC07-523LS (5 mg/kg Each) SC Multiple Dose Group* (*Only One Dose Received)</title>
          <description>10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)&#xD;
*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision.&#xD;
VRC-HIVMAB095-00-AB (10E8VLS): 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.&#xD;
VRC-HIVMAB075-00-AB (VRC07-523LS): VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site [10E8VLS] bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Administration site [10E8VLS] erythema</sub_title>
                <description>Redness</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Administration site [10E8VLS] pain/tenderness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Administration site [10E8VLS] pruritis</sub_title>
                <description>Itching</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Administration site [10E8VLS] swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Administration site [VRC07-523LS] erythema</sub_title>
                <description>Redness</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Injection site [VRC07-523LS site] erythema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Redness</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Temperature (Fever)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Joint pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study never resumed after the voluntary pause. Participants in the repeat-dose groups (2 and 4) were converted to a modified schedule per protocol. Study participation for all participants was approximately 24 weeks after Day 0 product administration. The overall population (N=8) was analyzed for the pharmacokinetic (PK) outcome measures as all study groups received only one 10E8VLS administration. Small group size has not allowed for meaningful PK analysis of each group separately.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Martin Gaudinski, MD</name_or_title>
      <organization>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</organization>
      <phone>301-451-8715</phone>
      <email>martin.gaudinski@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

